Jefferies puts MannKind on hold

Jefferies & Co., Inc. analyst Adam Walsh maintained MannKind Corp. at hold and increased its price target to $20 from $16. The analyst believes shares are fairly valued at current levels, with near-term clinical data presentations reflected in the current share price. MannKind's first-quarter loss per share was $0.09 below Jefferies' estimate. Shares of the Valencia, Calif., biopharmaceutical company were up 5 cents, or 0.25%, at $19.96 on volume of 131,031 shares versus the three-month running average of 308,657 shares. (Nasdaq: MNKD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.